AstraZeneca Plc said that its biologics arm, MedImmune, has reached agreement to acquire privately-held Amplimmune of Maryland, US in a move that will strengthen its portfolio of immune-mediated cancer therapies. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
